The Netherlands.
A decade ago, TNF was considered a promising new drug for cancer therapy. In vitro and in vivo experiments had shown a tumour-specific cell killing activity, but thus far the clinical results have been disappointing (Balkwill et al., 1990) . Severe toxicity of TNF, resembling a toxic shock syndrome, prevented the administration of dosages required for antitumour activity observed experimentally. Clinically relevant results were achieved in those situations where TNF could be administered either locally (van der Schelling et al., 1992) or regionally, such as by regional isolated perfusion (Lienard et al., 1992) , where the dose level that can be achieved within tumour tissues is considerably higher than with systemic administration.
Hyperthermia has been investigated clinically on a large scale since 1975. The possibilities of applying local hyperthermia have been increased by the development of new techniques.
In vitro and in vivo studies strongly suggested synergistic anti-tumour activity of combined hyperthermia and TNF-m. In vitro, the addition of hyperthermia was found to enhance the effect of TNF by a factor (TER = thermal enhancement ratio) of more than 500 (Watanabe et al., 1988) . The effects of the combination of TNF and hyperthermia in vivo were also demonstrated to be more than additive (Haranaka et al., 1987; Amano et al., 1990; Srinivasan et al., 1990; Fujimoto et al., 1991; Tomasovic et al., 1992) .
In view of the experimental findings, combining the two modalities could be beneficial. However, a possible disadvantage of this combination is that the systemic toxicity of TNF-a may also be enhanced by additional local hyperthermia, as was suggested by the findings of Amano et al. (1990) . All mice treated with the combination of TNF and hyperthermia died, whereas all mice treated with TNF at the same or even higher doses dunrng normothermia survived. In order to obtain safe starting dosages for a clinical phase I study on the application of deep local hyperthermia and systemic TNF treatment, we investigated the toxicity of local hyperthermia combined with systemic TNF-( as compared with TNF alone at normal body temperature.
Materials and methods
Animal and tumour system All procedures involving animals were carried out in accordance with the rules of the institutional Animal Ethical Committee. The various rectal and tumour temperatures are presented in Table I . The rectal temperature at the time that TNF was Tllr _.hic_i d n TW.a hcud dleci J van der Zee et a administered (rectal at start) had decreased in all animals owing to the anaesthesia. The mean rectal temperature (± s.e.) in the normothermia group was 36.72 ± 0.1 1C, which was 2C higher than measured at the start of treatment. The maximum rectal temperature was 38.11 ± O.lOC, which is within the range of normal systemic temperature in unanaesthetised rats (i.e. 37.5-38.5 C). In the hyperthermia group the mean rectal temperature measured was 38.28 ± 0.06°C (range 36.6-39.0°C). The mean temperature at the start of hyperthermia treatment (32.7 ± 0.15°C) was lower than in the normothermia group, because of a longer preparation time needed for the introduction of the intratumour catheters for thermometry. The maximum rectal temperature of 38.9 ± 0.05°C ( Fguwe 1 Dose-effect relationships for TNF-n-induced lethality.
Data for TNF at normothermia (-) and for TNF at hyperthermia (A). Bars = 95% confidence intervals. The thermal enhancement ratio at the LDO level is 5.3.
temperature. maximum and mean tumour temperature and rate of temperature increase, measured as the time needed to reach 42'C, were assessed using multivariate logistic models. In a few experiments temperatures were measured but not recorded owing to software failure. Therefore, in all multivariate models only those animals were included for which a complete data set was available (for tumour cure: TNF + HT, n = 28; TNF alone, n = 28; for lethality: TNF + HT, n = 47; TNF alone. n = 53). For this reduced number of animals, the TNF dose-effect relationship remained significant for the two types of treatment in the univariate model.
The incidence of lethality after TNF with or without hyperthermia was not influenced by tumour volume or by systemic (rectal) temperatures. In the combined therapy group. a significant effect of both maximum and mean tumour temperature on the death of the animals was observed (P = 0.037 and P = 0.047 respectively). The analysis indicated a decrease in the LD50 of TNF at a further increase in temperature. If. for instance, the maximum tumour temperature were to be increased from 42'C to 43'C, the LD50 value of TNF would decrease by a factor 3.6, from 454 to 126 Lg kg-'. The maximum tumour temperature was also significant (P = 0.016) in a univariate model, although inspection of the raw temperature data did not reveal a significant difference. Division of the relatively short range of temperatures (42.2-43.1 'C) into two categories of approx- imately equal size ( 42.6 and > 42.6'C) showed 8/24 (33%) deaths in the low-temperature group, against 17/29 (59%) in the high-temperature group (P = 0.19).
Tumour cure was not influenced by other factors in addition to the TNF dose in the group without hyperthermia. In the group receiving TNF plus hyperthermia however, tumour volume was an additional factor (P = 0.0009). Incorporating both TNF dose and tumour volume in the calculation of TCD50 values, the following doses were obtained: 40, 184, and 328 ggkg-' for volumes of 250, 500 and 1000mm3 respectively. Addition of temperature parameters (either alone or in combination with tumour volume) did not significantly improve the model containing only the TNF dose.
Discso. and conDchs
This study was designed to investigate whether local hyperthermia would enhance the systemic toxicity of intravenously administered TNF-a, to determine a safe level for a clinical phase I study with the combination of deep local hyperthermia and systemic TNF.
In our cancer institute, regional deep heating is administered to patients with the BSD-2000 system (Turner and Schaefermeyer, 1989 Thermal eamento TFW-induced effects van ridr 7Zp Pt al alternatively. after a maximum of 30 min heating. In the normal tissues surrounding the tumour a maximum temperature of 43C is allowed. Generally. in humans the systemic temperature increases 1-2°C (van der Ploeg et al.. 1992) . For this study. a similar hyperthermia application was chosen.
In view of experimental findings. demonstrating synergistic anti-tumour activity of TNF-a and hyperthermia both in vitro and in vivo. the combination of these two modalities appears an attractive option. However, the systemic toxicity of TNF-a may also be enhanced by additional local hyperthermia. as was suggested by Amano et al. (1990) . who reported that all 14 mice died following TNF at a dose of 5000 U or higher in combination with local hyperthermia (20 min at 43.5'C). whereas none of five animals died following 10 000 U of TNF at normothermia. Haranaka et al. (1987) also reported lethal toxicity of TNF in combination with total body hyperthermia at 41.5°C in mice, whereas no side-effects were observed at 40°C.
From these studies. however. the ratio of enhancement cannot be derived. Also. Amano et al. (1990) did not report on the systemic temperature during local hyperthermia. In their study. increased systemic temperatures may also have been responsible for the increased systemic toxicity compared with the TNF alone treatment. when the systemic temperature was probably relatively low owing to the anaesthesia.
Since it has been reported that the presence of a tumour may have a considerable impact on the systemic toxicity of TNF-x (Asher et al.. 1987 ). a tumour-bearing animal model was chosen for this study. This also enabled us to investigate the anti-tumour activity in both treatment arms.
Our results show an enhancement of systemic toxicity as measured by lethality with a factor 5.3. Since we found no correlation between the increase in systemic temperature and lethality rate within the TNF + hyperthermia group. there is no evidence that this enhanced toxicitv is caused by systemic hyperthermia.
On the contrary. the finding that the intra-tumour temperatures correlated positively with lethalitv suggests that the enhanced systemic toxicity is instigated by local effects of TNF at increased temperatures at the tumour site. A possible explanation may be that hy-perthermia triggers the cascade of events induced by TNF (Tomasovic and Klostergaard. 1989) . The cytocidal effects of hyperthermia are related to insufficient blood flow in cancer tissues. resulting in areas with hypoxia and low pH and. secondarily. to damage to tumour vasculature (Reinhold and Endnrch. 1986 ). Although little is known about the precise mode of action. TNF seems to cause tumour regression also by different mechanisms: both direct cytotoxic effects as evidenced by in vitro studies and alteration of the tumour vasculature and or the host immune system have been demonstrated. Whether increased damage to tumour vasculature by hyperthermia. or augmented direct cytotoxicity of TNF. is related to the enhancement demonstrated in this study remains to be determined. Since systemic toxicity enhancement is related to local tumour temperature. and TNF toxicity also appears related to the presence of a tumour (Asher et al.. 1987) . vasoactive or immunoactive mediators might be released in the circulation as an indirect result of the cytotoxicity by TNF. or the necrosis induced by the treatment.
Having defined a TER at the LD.O level in these tumourbearing Wag Rij rats of 5.3. we estimate that a safe starting dose of combined systemic TNF and local hyperthermia in humans would be 10% of the dose that has been recommended for phase II studies with single-agent bolus intravenous administration of TNF-z (Blick et al.. 1987 : Chapman et al.. 1987 Balkwill et al.. 1990 : Schiller et al.. 1991 ).
In our model the anti-tumour effect of TNF-x was enhanced by a factor 6.4. Whether this modest enhancement of anti-tumour activity at increased temperatures. as compared with the enhanced toxicity. has clinical usefulness has to be determined in clinical testing.
Systemic TNF toxicity was found to be enhanced by additional local hyperthermia. Further. it was found that a 1°C
higher maximum tumour temperature results in a further decrease in the LD^O dose of TNF by a factor 3.6. These findings imply that in the clinical situation. when the tumour temperature distribution generally is difficult to control (van der Zee et al.. 1986) . the combination of systemic TNF and * wal hypertherinia has to be applied with great caution. tumour necrosis factor alpha.
